Neoplasm Malignant Clinical Trials

8 recruiting

Neoplasm Malignant Trials at a Glance

28 actively recruiting trials for neoplasm malignant are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Not Applicable with 12 trials, with the heaviest enrollment activity in Milan, Fairfax, and Baltimore. Lead sponsors running neoplasm malignant studies include Merck Sharp & Dohme LLC, Centre Antoine Lacassagne, and Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC).

Browse neoplasm malignant trials by phase

Treatments under study

About Neoplasm Malignant Clinical Trials

Looking for clinical trials for Neoplasm Malignant? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoplasm Malignant trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoplasm Malignant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 2

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

Neoplasm Malignant
Merck Sharp & Dohme LLC150 enrolled46 locationsNCT07209111
Recruiting

Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer

Rectal Neoplasm Malignant
Chang Gung Memorial Hospital250 enrolled1 locationNCT06831669
Recruiting
Phase 1Phase 2

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC190 enrolled4 locationsNCT07286149
Recruiting
Phase 1

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

NeoplasmsNeoplasms by SiteBrain Diseases+30 more
M.D. Anderson Cancer Center24 enrolled3 locationsNCT03911388
Recruiting
Not Applicable

Confocal Laser Endomicroscopy VERification

Lung CancerLung Neoplasm Malignant
Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)208 enrolled5 locationsNCT06079970
Recruiting
Phase 2

Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Lung Neoplasm Malignant
Merck Sharp & Dohme LLC60 enrolled34 locationsNCT06788912
Recruiting
Not Applicable

Benefit of Spectral Information in Patients Suspected for Lung Cancer

Lung Neoplasm Malignant
Copenhagen University Hospital at Herlev1,000 enrolled1 locationNCT06440616
Recruiting

Step Count and Treatment Response in Neoadjuvant Breast Cancer

ExerciseBreast Cancer FemalesBreast Neoplasm Malignant Female+3 more
Ankara Etlik City Hospital82 enrolled2 locationsNCT07162675
Recruiting
Not Applicable

Telephone Support in Advanced Gastrointestinal Cancer

Caregiver BurdenGastrointestinal Neoplasm Malignant
Indiana University488 enrolled4 locationsNCT06532877
Recruiting
Phase 2

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

Drug ResistanceMetastatic Solid CancersRadiotherapy+3 more
Chuangzhen Chen48 enrolled1 locationNCT07071103
Recruiting
Not Applicable

Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

Neoplasm Malignant
Centre Antoine Lacassagne50 enrolled1 locationNCT06782451
Recruiting
Phase 2

Omission of Local Therapies in Women Patients With HER2-positive or Triple-negative Breast Cancer

Breast Neoplasm Malignant Female
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano152 enrolled1 locationNCT06938724
Recruiting
Not Applicable

TRUST-ACE - Anticancer-treatment Cardiotoxicity Identification by Echocardiography

Breast Neoplasm Malignant Primary
Norwegian University of Science and Technology250 enrolled1 locationNCT06310330
Recruiting

Genetics of Appendix Cancer Study

Appendiceal CancerAppendix CancerAppendiceal Adenocarcinoma+12 more
Andreana Holowatyj, PhD, MSCI700 enrolled1 locationNCT05734430
Recruiting
Not Applicable

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

Neoplasm Malignant
Centre Antoine Lacassagne238 enrolled1 locationNCT06606366
Recruiting
Phase 2

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

Endometrial Neoplasm Malignant Stage I
Fudan University104 enrolled1 locationNCT05247268
Recruiting

Preoperative vs. Pathologic Size in Breast Cancer: A Prospective Study

MastectomyBreast Neoplasm Malignant Primary
Incheon St.Mary's Hospital600 enrolled1 locationNCT06505577
Recruiting
Not Applicable

Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy

Mastectomy, SegmentalBreast Neoplasm Malignant Female
Tensive SRL92 enrolled3 locationsNCT05941299
Recruiting
Not Applicable

Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Lung Neoplasm Malignant
Ruijin Hospital20 enrolled1 locationNCT04973293
Recruiting

MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer

Lung Neoplasm Malignant
European Institute of Oncology270 enrolled2 locationsNCT05974475